Warning: The NCBI web site requires JavaScript to function. more...
Generate a file for use with external citation management software.
Is routine hysteroscopy during LLETZ a valuable additional procedure?
Ott J, Jatzko B, Nemeth Z, Wirth S, Wagner G.
Acta Obstet Gynecol Scand. 2011 Nov;90(11):1284-6. doi: 10.1111/j.1600-0412.2011.01235.x. Epub 2011 Aug 29.
Related citations
Cervical HIV-1 RNA shedding after cryotherapy among HIV-positive women with cervical intraepithelial neoplasia stage 2 or 3.
Chung MH, McKenzie KP, Richardson BA, John-Stewart GC, Coombs RW, De Vuyst H, Njoroge JW, Nyongesa-Malava E, Sakr SR, Mugo NR.
AIDS. 2011 Sep 24;25(15):1915-9.
IMP3, a new biomarker to predict progression of cervical intraepithelial neoplasia into invasive cancer.
Lu D, Yang X, Jiang NY, Woda BA, Liu Q, Dresser K, Mercurio AM, Rock KL, Jiang Z.
Am J Surg Pathol. 2011 Nov;35(11):1638-45.
Accuracy of 18-fluoro-2-deoxy-D-glucose positron emission tomography in the pretherapeutic detection of occult para-aortic node involvement in patients with a locally advanced cervical carcinoma.
Leblanc E, Gauthier H, Querleu D, Ferron G, Zerdoud S, Morice P, Uzan C, Lumbroso S, Lecuru F, Bats AS, Ghazzar N, Bannier M, Houvenaeghel G, Brenot-Rossi I, Narducci F.
Ann Surg Oncol. 2011 Aug;18(8):2302-9. Epub 2011 Feb 23.
Mast cell chymase is present in uterine cervical carcinoma and it detaches viable and growing cervical squamous carcinoma cells from substratum in vitro.
Diaconu NC, Rummukainen J, Naukkarinen A, Mättö M, Harvima RJ, Pelkonen J, Harvima IT.
Arch Dermatol Res. 2011 Sep;303(7):499-512. doi: 10.1007/s00403-011-1121-4. Epub 2011 Jan 29.
Outcomes and toxicities for the treatment of stage IVB cervical cancer.
Hwang JH, Lim MC, Seo SS, Kang S, Park SY, Kim JY.
Arch Gynecol Obstet. 2012 Jun;285(6):1685-93. Epub 2011 Dec 16.
Gynecologic cytology proficiency testing failures: what have we learned?: observations from the college of american pathologists gynecologic cytology proficiency testing program.
Ducatman BS, Bentz JS, Fatheree LA, Souers R, Ostrowski S, Moriarty AT, Henry M, Laucirica R, Booth CN, Wilbur DC.
Arch Pathol Lab Med. 2011 Nov;135(11):1442-6.
Spotlight on AS04-adjuvanted human papillomavirus (HPV) types 16 and 18 vaccine (Cervarix®).
McKeage K, Romanowski B.
BioDrugs. 2011 Aug 1;25(4):265-9. doi: 10.2165/11206830-000000000-00000.
Reduced expression of PHD2 prolyl hydroxylase gene in primary advanced uterine cervical carcinoma.
Roszak A, Kędzia W, Malkowska-Walczak B, Pawlik P, Kędzia H, Łuczak M, Lianeri M, Jagodzinski PP.
Biomed Pharmacother. 2011 Jul;65(4):298-302. Epub 2011 May 31.
Histological recurrence and depth of loop treatment of the cervix in women of reproductive age: incomplete excision versus adverse pregnancy outcome.
Soutter P, Ghaem-Maghami S.
BJOG. 2011 Nov;118(12):1536; author reply 1537. doi: 10.1111/j.1471-0528.2011.03125.x. No abstract available.
Canadian oncogenic human papillomavirus cervical infection prevalence: systematic review and meta-analysis.
Tricco AC, Ng CH, Gilca V, Anonychuk A, Pham B, Berliner S.
BMC Infect Dis. 2011 Sep 5;11:235. Review.
Use of HC2 to triage women with borderline and mild dyskaryosis in the UK.
Arbyn M, Roelens J, Martin-Hirsch P, Leeson S, Wentzensen N.
Br J Cancer. 2011 Sep 27;105(7):877-80. doi: 10.1038/bjc.2011.351. No abstract available.
HPV testing as a triage for borderline or mild dyskaryosis on cervical cytology: results from the Sentinel Sites study.
Kelly RS, Patnick J, Kitchener HC, Moss SM; NHSCSP HPV Special Interest Group.
Br J Cancer. 2011 Sep 27;105(7):983-8. doi: 10.1038/bjc.2011.326. Epub 2011 Sep 6.
Paclitaxel-ifosfamide-carboplatin combination chemotherapy regimen in advanced uterine and adnexal malignant mixed Mullerian tumours.
Kosmas C, Vorgias G, Tsakonas G, Politis P, Daladimos T, Panagiotidi E, Papachrysanthou T, Moschovis D, Kalinoglou N, Tsavaris N, Karabelis A, Mylonakis N.
Br J Cancer. 2011 Sep 27;105(7):897-902. doi: 10.1038/bjc.2011.316. Epub 2011 Aug 16.
Should the organs at risk be contoured in vaginal cuff brachytherapy?
Holloway CL, Macklin EA, Cormack RA, Viswanathan AN.
Brachytherapy. 2011 Jul-Aug;10(4):313-7. Epub 2010 Dec 30.
Cytologic-histologic correlation.
Raab SS, Grzybicki DM.
Cancer Cytopathol. 2011 Oct 25;119(5):293-309. doi: 10.1002/cncy.20165. Epub 2011 Jul 5. Review.
Suppression of carbonyl reductase expression enhances malignant behaviour in uterine cervical squamous cell carcinoma: carbonyl reductase predicts prognosis and lymph node metastasis.
Murakami A, Fukushima C, Yoshidomi K, Sueoka K, Nawata S, Yokoyama Y, Tsuchida S, Ismail E, Al-Mulla F, Sugino N.
Cancer Lett. 2011 Dec 1;311(1):77-84. Epub 2011 Jul 13.
Cervical cancer prevention in low- and middle-income countries: feasible, affordable, essential.
Sahasrabuddhe VV, Parham GP, Mwanahamuntu MH, Vermund SH.
Cancer Prev Res (Phila). 2012 Jan;5(1):11-7. Epub 2011 Dec 12. Review.
The use of a human papillomavirus 18 promoter for tissue-specific expression in cervical carcinoma cells.
Lung MS, Mak WM, Murray V.
Cell Mol Biol Lett. 2011 Sep;16(3):477-92. Epub 2011 Jul 18.
Molecular epidemiology of HPV infection using a clinical array methodology in 2952 women in Greece.
Tsiodras S, Hatzakis A, Spathis A, Margari N, Meristoudis C, Chranioti A, Kyrgiou M, Panayiotides J, Kassanos D, Petrikkos G, Nasioutziki M, Loufopoulos A, Paraskevaidis E, Karakitsos P.
Clin Microbiol Infect. 2011 Aug;17(8):1185-8. doi: 10.1111/j.1469-0691.2011.03505.x. Epub 2011 May 20.
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on